Voyager Therapeutics, Inc.

NASDAQ:VYGR

6.25 (USD) • At close September 13, 2024
Bedrijfsnaam Voyager Therapeutics, Inc.
Symbool VYGR
Munteenheid USD
Prijs 6.25
Beurswaarde 340,833,125
Dividendpercentage 0%
52-weken bereik 5.97 - 11.72
Industrie Biotechnology
Sector Healthcare
CEO Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Website https://www.voyagertherapeutics.com

An error occurred while fetching data.

Over Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral

Vergelijkbare Aandelen

Verastem, Inc. logo

Verastem, Inc.

VSTM

2.81 USD

Liquidia Corporation logo

Liquidia Corporation

LQDA

9.795 USD

The Joint Corp. logo

The Joint Corp.

JYNT

12 USD

Theratechnologies Inc. logo

Theratechnologies Inc.

THTX

1.35 USD

Ocular Therapeutix, Inc. logo

Ocular Therapeutix, Inc.

OCUL

9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)